This Editorial discusses the US Preventive Services Task Force recommendations statement on screening for lipid disorders in children and adolescents and the low value this screening has.
This secondary analysis of a randomized clinical trial assesses the effect of pharmacologic therapy and clinical risk factors on incident conduction system disease in patients with hypertension.
This review assesses the relative merits of using nonfasting blood draws for routine lipid testing.
This Viewpoint discusses the implications of recent circuit court decisions regarding commercial speech and off-label marketing of prescription drugs.
Downing et al review news stories and biomedical literature discussing the Action to Control Cardiovascular Risk in Diabetes (ACCORD-Lipid) trial published within 15 months after results of the trial were presented.
To determine the frequency and correlates of repeat lipid testing in 35 191 VA patients with CHD who attained LDL-C goals and received no treatment intensification, Virani et al performed logistic regression analyses to evaluate facility, provider, and patient characteristics associated with repeat testing. See the Invited Commentary by Drozda and the Editor’s Note by Covinsky.